pyruvic acid has been researched along with Anemia, Sickle Cell in 3 studies
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
Excerpt | Relevance | Reference |
---|---|---|
" After daily dosing of etavopivat over 5 consecutive days in NHPs, ATP was increased by 38% from baseline." | 1.72 | Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. ( Drake, A; Fessler, R; Forsyth, S; Fulzele, K; Guichard, S; Kalfa, TA; Konstantinidis, DG; Marshall, CG; Ribadeneira, MD; Schroeder, P; Seu, KG; Wilker, E, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 3 (100.00) | 2.80 |
Authors | Studies |
---|---|
Schroeder, P | 1 |
Fulzele, K | 1 |
Forsyth, S | 1 |
Ribadeneira, MD | 1 |
Guichard, S | 1 |
Wilker, E | 1 |
Marshall, CG | 1 |
Drake, A | 1 |
Fessler, R | 1 |
Konstantinidis, DG | 1 |
Seu, KG | 1 |
Kalfa, TA | 1 |
Xu, JZ | 1 |
Conrey, A | 1 |
Frey, I | 1 |
Gwaabe, E | 1 |
Menapace, LA | 1 |
Tumburu, L | 1 |
Lundt, M | 1 |
Lequang, T | 1 |
Li, Q | 1 |
Glass, K | 1 |
Dunkelberger, EB | 1 |
Iyer, V | 1 |
Mangus, H | 1 |
Kung, C | 1 |
Dang, L | 1 |
Kosinski, PA | 1 |
Hawkins, P | 1 |
Jeffries, N | 1 |
Eaton, WA | 1 |
Lay Thein, S | 1 |
Little, JA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects With Stable Sickle Cell Disease[NCT04000165] | Early Phase 1 | 17 participants (Actual) | Interventional | 2019-07-11 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
To assess the clinical safety and tolerability of multiple escalating doses of AG-348, an allosteric activator of the enzyme pyruvate kinase, in subjects with stable sickle cell disease (SCD). Safety and tolerability were assessed by defined as a ≥ 1 g/dL increase in hemoglobin at any dose level compared to baseline. (NCT04000165)
Timeframe: 14 weeks
Intervention | Participants (Count of Participants) |
---|---|
AG-348 in Participants With Sickle Cell Disease | 9 |
To assess the clinical safety and tolerability of multiple escalating doses of AG-348, an allosteric activator of the enzyme pyruvate kinase, in subjects with stable sickle cell disease (SCD). Safety and tolerability were assessed by frequency and severity of adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) 5.0. (NCT04000165)
Timeframe: 14 weeks
Intervention | Participants (Count of Participants) |
---|---|
AG-348 in Participants With Sickle Cell Disease | 2 |
To assess change in absolute reticulocyte count in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks
Intervention | K/mcL (Mean) | ||||||
---|---|---|---|---|---|---|---|
Baseline | 5 mg dose of AG-348 | 20 mg dose AG-348 | 50 mg dose AG-348 | 100 mg dose AG-348 | End of Taper Dose AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | 196.44 | -20.97 | -20.72 | -44.99 | -34.1 | -13.77 | 8.1 |
To assess change in aspartate aminotransferase (AST) in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks
Intervention | U/L (Mean) | ||||||
---|---|---|---|---|---|---|---|
Baseline | 5 mg dose of AG-348 | 20 mg dose AG-348 | 50 mg dose AG-348 | 100 mg dose AG-348 | End of Taper Dose AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | 33.88 | -3.31 | -3.37 | -2 | -3.54 | -2.49 | 3.02 |
To assess the change in fetal hemoglobin (HbF) in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks
Intervention | Percent HbF (Mean) | ||||||
---|---|---|---|---|---|---|---|
Baseline | 5 mg dose of AG-348 | 20 mg dose AG-348 | 50 mg dose AG-348 | 100 mg dose AG-348 | End of Taper Dose AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | 20.39 | -0.42 | -1.02 | -1.31 | -0.34 | 0.19 | 0.81 |
To assess change in hemoglobin in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks
Intervention | g/dL (Mean) | ||||||
---|---|---|---|---|---|---|---|
Baseline | 5 mg dose of AG-348 | 20 mg dose AG-348 | 50 mg dose AG-348 | 100 mg dose AG-348 | End of Taper Dose AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | 8.73 | 0.34 | 0.76 | 1.19 | 0.92 | 0.34 | 0.37 |
To assess change in lactic acid dehydrogenase (LDH) in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks
Intervention | U/L (Mean) | ||||||
---|---|---|---|---|---|---|---|
Baseline | 5 mg dose of AG-348 | 20 mg dose AG-348 | 50 mg dose AG-348 | 100 mg dose AG-348 | End of Taper Dose AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | 348.4 | -7.81 | -39.94 | -25.31 | -37.89 | 20.63 | 30.72 |
To assess change in mean corpuscular volume (MCV) in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks
Intervention | fL (Mean) | ||||||
---|---|---|---|---|---|---|---|
Baseline | 5 mg dose of AG-348 | 20 mg dose AG-348 | 50 mg dose AG-348 | 100 mg dose AG-348 | End of Taper Dose AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | 103.32 | -0.5 | 0.52 | 0.42 | 1.98 | -0.25 | -0.64 |
To assess change in total bilirubin in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks
Intervention | mg/dL (Mean) | ||||||
---|---|---|---|---|---|---|---|
Baseline | 5 mg dose of AG-348 | 20 mg dose AG-348 | 50 mg dose AG-348 | 100 mg dose AG-348 | End Of Taper Dose AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | 1.82 | -0.19 | -0.56 | -0.77 | -0.87 | -0.19 | 0.1 |
To assess the clinical safety and tolerability of multiple escalating doses of AG-348, an allosteric activator of the enzyme pyruvate kinase, in subjects with stable sickle cell disease (SCD). Safety and tolerability were assessed by frequency and severity of adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) 5.0. (NCT04000165)
Timeframe: 14 weeks
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Insomnia | Arthralgia | Hypertension | |
AG-348 in Participants With Sickle Cell Disease | 6 | 3 | 3 |
Measure percent change from baseline in oxygen binding p50 value at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks
Intervention | Percent Change (Mean) | |||||
---|---|---|---|---|---|---|
5 mg Dose AG-348 | 20 mg Dose AG-348 | 50 mg Dose AG-348 | 100 mg Dose AG-348 | End of Taper Dose AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | 0.5 | -2.09 | -3.84 | -4.88 | 7.97 | 10.79 |
To understand the mechanisms of action of AG- 348 on the glycolytic pathway in sickle cell disease through laboratory studies of specific pharmacodynamics of 2,3-DPG at each dose level of AG-348. (NCT04000165)
Timeframe: 14 weeks
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
5 mg Dose AG-348 | 20 mg Dose AG-348 | 50 mg Dose AG-348 | 100 mg Dose AG-348 | End of Taper Dose AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | -3.74 | -16.08 | -23.49 | -24.13 | 1.97 | 9.11 |
To understand the mechanisms of action of AG- 348 on the glycolytic pathway in sickle cell disease through laboratory studies of specific pharmacodynamics of adenosine triphosphate (ATP) at each dose level of AG-348. (NCT04000165)
Timeframe: 14 weeks
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
5 mg Dose AG-348 | 20 mg Dose AG-348 | 50 mg Dose AG-348 | 100 mg Dose AG-348 | End of Taper Dose AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | 13.68 | 26.95 | 33.43 | 39.84 | 15.51 | 12.03 |
Measure percent change in Time (mins) at which 50% of red blood cells are sickled (t50) Value at Each Dose Level of AG-348 (NCT04000165)
Timeframe: 14 weeks
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
5 mg Dose AG-348 | 20 mg Dose AG-348 | 50 mg Dose AG-348 | 100 mg Dose AG-348 | End of Taper AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | -0.46 | 10.19 | 7.11 | 13.98 | -11.38 | 1.67 |
To understand the mechanisms of action of AG- 348 on the glycolytic pathway in sickle cell disease through laboratory studies of specific pharmacodynamics of PK-R at each dose level of AG-348. (NCT04000165)
Timeframe: 14 weeks
Intervention | percent change (Mean) | |||||
---|---|---|---|---|---|---|
5 mg Dose AG-348 | 20 mg Dose AG-348 | 50 mg Dose AG-348 | 100 mg Dose AG-348 | End of Taper AG-348 | End of Study AG-348 | |
AG-348 in Participants With Sickle Cell Disease | -6.89 | -2.82 | -10.66 | -28.99 | -8.38 | -16.47 |
1 trial available for pyruvic acid and Anemia, Sickle Cell
Article | Year |
---|---|
A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.
Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Adult; Anemia, Sickle Cell; Hemoglobins; Humans; Pyr | 2022 |
2 other studies available for pyruvic acid and Anemia, Sickle Cell
Article | Year |
---|---|
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Anemia, Sickle Cell; Animals; Erythrocytes; Hemoglob | 2022 |
RBC, heal thyself: PK activators in SCD.
Topics: Anemia, Sickle Cell; Humans; Piperazines; Pyruvate Kinase; Pyruvic Acid | 2022 |